Elanco Animal Health Inc
NYSE:ELAN
Elanco Animal Health Inc
Cash from Operating Activities
Elanco Animal Health Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Elanco Animal Health Inc
NYSE:ELAN
|
Cash from Operating Activities
$271m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$23.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$14.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$3.7B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
See Also
What is Elanco Animal Health Inc's Cash from Operating Activities?
Cash from Operating Activities
271m
USD
Based on the financial report for Dec 31, 2023, Elanco Animal Health Inc's Cash from Operating Activities amounts to 271m USD.
What is Elanco Animal Health Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-11%
Over the last year, the Cash from Operating Activities growth was -40%.